- Home
- MYGN vs MIRM Comparison
MYGN vs MIRM Comparison
Compare MYGN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- MIRM
- Stock Information
- Founded
- MYGN 1991
- MIRM 2018
- Country
- MYGN United States
- MIRM United States
- Employees
- MYGN N/A
- MIRM N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- MIRM Health Care
- Exchange
- MYGN Nasdaq
- MIRM Nasdaq
- Market Cap
- MYGN 744.7M
- MIRM 2.5B
- IPO Year
- MYGN 1995
- MIRM 2019
- Fundamental
- Price
- MYGN $5.34
- MIRM $52.66
- Analyst Decision
- MYGN Hold
- MIRM Strong Buy
- Analyst Count
- MYGN 15
- MIRM 9
- Target Price
- MYGN $15.14
- MIRM $66.22
- AVG Volume (30 Days)
- MYGN 1.4M
- MIRM 465.4K
- Earning Date
- MYGN 08-05-2025
- MIRM 08-06-2025
- Dividend Yield
- MYGN N/A
- MIRM N/A
- EPS Growth
- MYGN N/A
- MIRM N/A
- EPS
- MYGN N/A
- MIRM N/A
- Revenue
- MYGN $831,300,000.00
- MIRM $379,251,000.00
- Revenue This Year
- MYGN N/A
- MIRM $35.83
- Revenue Next Year
- MYGN $6.68
- MIRM $16.83
- P/E Ratio
- MYGN N/A
- MIRM N/A
- Revenue Growth
- MYGN 7.38
- MIRM 69.31
- 52 Week Low
- MYGN $3.81
- MIRM $36.17
- 52 Week High
- MYGN $29.30
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- MIRM 64.66
- Support Level
- MYGN $4.90
- MIRM $49.22
- Resistance Level
- MYGN $5.83
- MIRM $53.86
- Average True Range (ATR)
- MYGN 0.28
- MIRM 1.57
- MACD
- MYGN 0.04
- MIRM 0.08
- Stochastic Oscillator
- MYGN 54.21
- MIRM 79.63
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.